Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 mai 2013 09h00 HE | Source: Lpath, Inc.

Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP

SAN DIEGO, May 30, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark...
23 mai 2013 09h00 HE | Source: Lpath, Inc.

Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP

SAN DIEGO, May 23, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics,has initiated dosing in a Phase 2a single-arm trial where...
16 avr. 2013 16h15 HE | Source: Lpath, Inc.

Lpath Adds Two Key Members to its Executive Team

SAN DIEGO, April 16, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics, has added two key members to its leadership team. Dario A....